Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

180 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT).
Hanna CR, O'Cathail SM, Graham JS, Saunders M, Samuel L, Harrison M, Devlin L, Edwards J, Gaya DR, Kelly CA, Lewsley LA, Maka N, Morrison P, Dinnett L, Dillon S, Gourlay J, Platt JJ, Thomson F, Adams RA, Roxburgh CSD. Hanna CR, et al. Among authors: graham js. Radiat Oncol. 2021 Aug 26;16(1):163. doi: 10.1186/s13014-021-01888-1. Radiat Oncol. 2021. PMID: 34446053 Free PMC article.
Adjuvant therapy in colon cancer.
Graham JS, Cassidy J. Graham JS, et al. Expert Rev Anticancer Ther. 2012 Jan;12(1):99-109. doi: 10.1586/era.11.189. Expert Rev Anticancer Ther. 2012. PMID: 22149436 Review.
Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial.
Joharatnam-Hogan N, Cafferty F, Hubner R, Swinson D, Sothi S, Gupta K, Falk S, Patel K, Warner N, Kunene V, Rowley S, Khabra K, Underwood T, Jankowski J, Bridgewater J, Crossley A, Henson V, Berkman L, Gilbert D, Kynaston H, Ring A, Cameron D, Din F, Graham J, Iveson T, Adams R, Thomas A, Wilson R, Pramesh CS, Langley R; Add-Aspirin Trial Management Group. Joharatnam-Hogan N, et al. Lancet Gastroenterol Hepatol. 2019 Nov;4(11):854-862. doi: 10.1016/S2468-1253(19)30289-4. Epub 2019 Aug 30. Lancet Gastroenterol Hepatol. 2019. PMID: 31477558 Free article. Clinical Trial.
Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer.
Roseweir AK, Park JH, Hoorn ST, Powell AG, Aherne S, Roxburgh CS, McMillan DC, Horgan PG, Ryan E, Sheahan K, Vermeulen L, Paul J, Harkin A, Graham J, Sansom O, Church DN, Tomlinson I, Saunders M, Iveson TJ, Edwards J. Roseweir AK, et al. J Pathol Clin Res. 2020 Oct;6(4):283-296. doi: 10.1002/cjp2.171. Epub 2020 May 13. J Pathol Clin Res. 2020. PMID: 32401426 Free PMC article.
The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer.
Alexander PG, Roseweir AK, Pennel KAF, van Wyk HC, Powell AGMT, McMillan DC, Horgan PG, Kelly C, Hay J, Sansom O, Harkin A, Roxburgh CSD, Graham J, Church DN, Tomlinson I, Saunders M, Iveson TJ, Edwards J, Park JH. Alexander PG, et al. Br J Cancer. 2021 Feb;124(4):786-796. doi: 10.1038/s41416-020-01168-x. Epub 2020 Nov 23. Br J Cancer. 2021. PMID: 33223535 Free PMC article.
Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial.
Adams RA, Fisher DJ, Graham J, Seligmann JF, Seymour M, Kaplan R, Yates E, Parmar M, Richman SD, Quirke P, Butler R, Brown E, Collinson F, Falk S, Wasan H, Shiu KK, Middleton G, Samuel L, Wilson RH, Brown LC, Maughan TS; FOCUS4 Trial Investigators. Adams RA, et al. J Clin Oncol. 2021 Nov 20;39(33):3693-3704. doi: 10.1200/JCO.21.01436. Epub 2021 Sep 13. J Clin Oncol. 2021. PMID: 34516759 Free PMC article. Clinical Trial.
180 results